Drug intelligence / Profile preview

SNA010

Development stage: Preclinical
Lead developer: SmartNuclide
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SNA010 is a preclinical-stage radiopharmaceutical diagnostic imaging agent being developed by SmartNuclide (Suzhou SmartNuclide Biopharmaceutical). It is designed to target the Thyroid Stimulating Hormone (TSH) receptor or related pathways for the imaging of solid tumors. As a radiopharmaceutical imaging agent, it likely utilizes a radioactive isotope conjugated to a targeting moiety to enable visualization of tumor tissues via nuclear medicine imaging techniques such as PET or SPECT. The agent is intended to assist in the detection, localization, and monitoring of tumors that express the target.

Targets

TSHR (Thyroid-stimulating hormone receptor)

Beyond the preview

Go deeper on SNA010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNA010.

Explore the full profile